Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib: The my-PAC study

Authors

James M. Rossetti
Abiola Oladapo (ORCID: https://orcid.org/0000-0001-6222-2491)
Bruce Feinberg
Michael Vredenburg (ORCID: https://orcid.org/0000-0001-7691-8027)
Caleb Paydar (ORCID: https://orcid.org/0000-0003-1636-5947)
Djibril Liassou
Naveen Pemmaraju (ORCID: https://orcid.org/0000-0002-1670-6513)
Michael Marrone (ORCID: https://orcid.org/0000-0003-1568-9499)
Puja Aggarwal
Douglas Tremblay (ORCID: https://orcid.org/0000-0003-2584-6953)
Purvi Suthar
Adina Gegprifti

Institutions

The University of Texas MD Anderson Cancer Center (US)
Cardinal Health (Ireland) (IE)
BG Medicine (United States) (US)
Cardinal Health (United States) (US)
Pittsburg State University (US)
Icahn School of Medicine at Mount Sinai (US)

Publication Details

Journal: Blood
Published: 2025-11-03
DOI: https://doi.org/10.1182/blood-2025-5577
Primary Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib: The my-PAC study

James M. Rossetti, Abiola Oladapo, Bruce Feinberg, Michael Vredenburg et al.

Nov 3, 2025

Blood

Myeloproliferative Neoplasms: Diagnosis and Treatment

article

Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib: The my-PAC study

James M. Rossetti, Abiola Oladapo, Bruce Feinberg, Michael Vredenburg, Caleb Paydar, Djibril Liassou, Naveen Pemmaraju, Michael Marrone, Puja Aggarwal, Douglas Tremblay, Purvi Suthar, Adina Gegprifti

November 3, 2025article en

Abstract

No abstract available for this paper.

BloodVol. 146(Supplement 1)

The University of Texas MD Anderson Cancer Center (US), Cardinal Health (Ireland) (IE), BG Medicine (United States) (US), Cardinal Health (United States) (US), Pittsburg State University (US), Icahn School of Medicine at Mount Sinai (US)

Openalex Percentile: Top 41%

Myeloproliferative Neoplasms: Diagnosis and Treatment

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib: The my-PAC study — James M. Rossetti, Abiola Oladapo, et al. · Blood (2025) | TGRS Research Map | TGRS